The association of diabetes and dementia and possible implications for nondiabetic populations

Expert Review of Neurotherapeutics

Volumn 11, Issue 11, 2011, Pages 1609-1617

  Ravona Springer, Ramit ^a   Schnaider Beeri, Michal ^b  

^a SHEBA MEDICAL CENTER   (Israel)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

advanced glycation end products; antidiabetic medications; cognition; dementia; diabetes; hypoglycemia; insulin resistance; mild cognitive impairment; neuropathology; vascular

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANTIDIABETIC AGENT; APOLIPOPROTEIN E EPSILON4; APOLIPOPROTEIN E4; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; BRAIN FUNCTION; CEREBROVASCULAR DISEASE; COGNITION; DEMENTIA; DIABETES CONTROL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG POTENTIATION; HUMAN; INSULIN RESISTANCE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; REVIEW; VASCULAR DISEASE;

DEMENTIA; DIABETES MELLITUS, TYPE 2; HUMANS; PREDIABETIC STATE; RISK FACTORS;

EID: 80054901333     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.152     Document Type: Review

References (109)

1. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch. Neurol. 61(5), 661-666 (2004)
2. Luchsinger JA, Reitz C, Patel B, Tang MX, Manly JJ, Mayeux R. Relation of diabetes to mild cognitive impairment. Arch. Neurol. 64(4), 570-575 (2007)
3. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am. J Epidemiol. 154(7), 635-641 (2001)
4. Luchsinger JA. Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: an epidemiological perspective. Eur J. Pharmacol. 585(1), 119-129 (2008)
5. Schnaider Beeri M, Goldbourt U, Silverman JM et al. Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology 63(10), 1902-1907 (2004)
6. Ahtiluoto S, Polvikoski T, Peltonen M et al. Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology 75(13), 1195-1202 (2010)
7. Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 51(4), 1256-1262 (2002)
8. Leibson CL, Rocca WA, Hanson VA et al. The risk of dementia among persons with diabetes mellitus: a population-based cohort study. Ann NY Acad.Sci. 826, 422-427 (1997)
9. Ott A, Stolk RP, Van HF, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 53(9), 1937-1942 (1999)
10. Rasgon NL, Kenna HA, Wroolie TE et al. Insulin resistance and hippocampal volume in women at risk for Alzheimer's disease. Neurobiol. Aging 32(11), 1942-1948 (2010)
11. Yaffe K, Blackwell T, Kanaya AM, Davidowitz N, Barrett-Connor E, Krueger K. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 63(4), 658-663 (2004)
12. Gregg EW, Yaffe K, Cauley JA et al. Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group. Arch. Intern. Med. 160(2), 174-180 (2000)
13. Haan MN, Shemanski L, Jagust WJ, Manolio TA, Kuller L. The role of APOE e4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA 282(1), 40-46 (1999)
14. Xu W, Caracciolo B, Wang HX et al. Accelerated progression from mild cognitive impairment to dementia in people with diabetes. Diabetes 59(11), 2928-2935 (2010)
15. Thomas VS, Darvesh S, Macknight C, Rockwood K. Estimating the prevalence of dementia in elderly people: a comparison of the Canadian Study of Health and Aging and National Population Health Survey approaches. Int. Psychogeriatr. 13(Suppl. 1), 169-175 (2001)
16. Ravona-Springer R, Luo X, Schmeidler J et al. Diabetes is associated with increased rate of cognitive decline in questionably demented elderly. Dement. Geriatr. Cogn. Disord. 29(1), 68-74 (2010)
17. Kalmijn S, Feskens EJ, Launer LJ, Kromhout D. Cerebrovascular disease, the apolipoprotein e4 allele, and cognitive decline in a community-based study of elderly men. Stroke 27(12), 2230-2235 (1996)
18. Kanaya AM, Barrett-Connor E, Gildengorin G, Yaffe K. Change in cognitive function by glucose tolerance status in older adults: a 4-year prospective study of the Rancho Bernardo study cohort. Arch. Intern. Med. 164(12), 1327-1333 (2004)
19. Van Den Berg E, De Craen AJ, Biessels GJ, Gussekloo J, Westendorp RG. The impact of diabetes mellitus on cognitive decline in the oldest of the old: a prospective population-based study. Diabetologia 49(9), 2015-2023 (2006)
20. Sanz C, Andrieu S, Sinclair A, Hanaire H, Vellas B. Diabetes is associated with a slower rate of cognitive decline in Alzheimer disease. Neurology 73(17), 1359-1366 (2009)
21. American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes Care 33(Suppl. 1), S62-S69 (2010)
22. Lu FP, Lin KP, Kuo HK. Diabetes and the risk of multi-system aging phenotypes: a systematic review and meta-analysis. PLoS One 4(1), e4144 (2009)
23. Profenno LA, Porsteinsson AP, Faraone SV. Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol. Psychiatry 67(6), 505-512 (2010)
24. Beeri MS, Silverman JM, Davis KL et al. Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology. J Gerontol. A Biol. Sci. Med. Sci. 60(4), 471-475 (2005)
25. Hoogwerf BJ, Young JB. The HOPE study. Ramipril lowered cardiovascular risk, but vitamin E did not. Cleve. Clin. J Med. 67(4), 287-293 (2000)
26. Blum S, Vardi M, Brown JB et al. Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype. Pharmacogenomics 11(5), 675-684 (2010)
27. Blum S, Vardi M, Levy NS, Miller-Lotan R, Levy AP. The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Atherosclerosis 211(1), 25-27 (2010)
28. Triplitt C. Cardiac risk factors and hypoglycemia in an elderly patient: how good is good enough? Consult. Pharm. 25(Suppl. B), 19-27 (2010)
29. Gerstein HC, Miller ME, Genuth S et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N. Engl. J Med. 364(9), 818-828 (2011)
30. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J Med. 358(24), 2545-2559 (2008)
31. Cavalieri M, Ropele S, Petrovic K et al. Metabolic syndrome, brain magnetic resonance imaging, and cognition. Diabetes Care 33(12), 2489-2495 (2010)
32. Luchsinger JA. Diabetes, related conditions, and dementia. J Neurol. Sci. 299(1-2), 35-38 (2010)
33. Power MC, Weuve J, Gagne JJ, Mcqueen MB, Viswanathan A, Blacker D. The association between blood pressure and incident Alzheimer disease: a systematic review and meta-analysis. Epidemiology 22(5), 646-659 (2011)
34. Enzinger C, Fazekas F, Matthews PM et al. Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects. Neurology 64(10), 1704-1711 (2005)
35. Yaffe K, Blackwell T, Whitmer RA, Krueger K, Barrett Connor E. Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women. J Nutr. Health Aging 10(4), 293-295 (2006)
36. Miyakawa T. Vascular pathology in Alzheimer's disease. Psychogeriatrics 10(1), 39-44 (2010)
37. Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 3(3), 169-178 (2004)
38. Munch G, Schinzel R, Loske C et al. Alzheimer's disease -synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm. 105(4-5), 439-461 (1998)
39. Tuppo EE, Arias HR. The role of inflammation in Alzheimer's disease. Int. J Biochem. Cell. Biol. 37(2), 289-305 (2005)
40. Kapogiannis D, Mattson MP. Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease. Lancet Neurol. 10(2), 187-198 (2011)
41. Fernandez-Gamba A, Leal MC, Morelli L, Castano EM. Insulin-degrading enzyme: structure-function relationship and its possible roles in health and disease. Curr Pharm. Des. 15(31), 3644-3655 (2009)
42. Nelson PT, Head E, Schmitt FA et al. Alzheimer's disease is not 'brain aging': neuropathological, genetic, and epidemiological human studies. Acta Neuropathol. 121(5), 571-587 (2011)
43. Heitner J, Dickson D. Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects. A retrospective postmortem immunocytochemical and histofluorescent study. Neurology 49(5), 1306-1311 (1997)
44. Nelson PT, Smith CD, Abner EA et al. Human cerebral neuropathology of Type 2 diabetes mellitus. Biochim. Biophys. Acta 1792(5), 454-469 (2009)
45. Arvanitakis Z, Schneider JA, Wilson RS et al. Diabetes is related to cerebral infarction but not to AD pathology in older persons. Neurology 67(11), 1960-1965 (2006)
46. Van Harten B, De Leeuw FE, Weinstein HC, Scheltens P, Biessels GJ. Brain imaging in patients with diabetes: a systematic review. Diabetes Care 29(11), 2539-2548 (2006)
47. Gorelick PB, Scuteri A, Black SE et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42(9), 2672-2713 (2011)
48. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277(10), 813-817 (1997)
49. Beeri MS, Schmeidler J, Silverman JM et al. Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology. Neurology 71(10), 750-757 (2008)
50. Craft S. The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch. Neurol. 66(3), 300-305 (2009)
51. Havrankova J, Roth J, Brownstein M. Insulin receptors are widely distributed in the central nervous system of the rat. Nature 272(5656), 827-829 (1978)
52. Baskin DG, Figlewicz DP, Woods SC, Porte D Jr, Dorsa DM. Insulin in the brain. Annu. Rev. Physiol. 49, 335-347 (1987)
53. Kenyon CJ. The genetics of ageing. Nature 464(7288), 504-512 (2010)
54. Park CR, Seeley RJ, Craft S, Woods SC. Intracerebroventricular insulin enhances memory in a passive-avoidance task. Physiol. Behav. 68(4), 509-514 (2000)
55. Fehm HL, Perras B, Smolnik R, Kern W, Born J. Manipulating neuropeptidergic pathways in humans: a novel approach to neuropharmacology? Eur. J Pharmacol. 405(1-3), 43-54 (2000)
56. Craft S, Asthana S, Newcomer JW et al. Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch. Gen. Psychiatry 56(12), 1135-1140 (1999)
57. Zhao W, Chen H, Xu H et al. Brain insulin receptors and spatial memory. Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats. J Biol. Chem. 274(49), 34893-34902 (1999)
58. Schulingkamp RJ, Pagano TC, Hung D, Raffa RB. Insulin receptors and insulin action in the brain: review and clinical implications. Neurosci. Biobehav. Rev. 24(8), 855-872 (2000)
59. Apelt J, Mehlhorn G, Schliebs R. Insulin-sensitive GLUT4 glucose transporters are colocalized with GLUT3-expressing cells and demonstrate a chemically distinct neuron-specific localization in rat brain. J Neurosci. Res. 57(5), 693-705 (1999)
60. Skeberdis VA, Lan J, Zheng X, Zukin RS, Bennett MV. Insulin promotes rapid delivery of N-methyl-d-aspartate receptors to the cell surface by exocytosis. Proc Natl Acad. Sci. USA 98(6), 3561-3566 (2001)
61. Kopf SR, Baratti CM. Effects of posttraining administration of insulin on retention of a habituation response in mice: participation of a central cholinergic mechanism. Neurobiol. Learn. Mem. 71(1), 50-61 (1999)
62. Figlewicz DP, Szot P, Israel PA, Payne C, Dorsa DM. Insulin reduces norepinephrine transporter mRNA in vivo in rat locus coeruleus. Brain Res. 602(1), 161-164 (1993)
63. Hong M, Lee VM. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol. Chem. 272(31), 19547-19553 (1997)
64. Lesort M, Johnson GV. Insulin-like growth factor-1 and insulin mediate transient site-selective increases in tau phosphorylation in primary cortical neurons. Neuroscience 99(2), 305-316 (2000)
65. Cheng CM, Tseng V, Wang J, Wang D, Matyakhina L, Bondy CA. Tau is hyperphosphorylated in the insulin-like growth factor-I null brain. Endocrinology 146(12), 5086-5091 (2005)
66. Tournoy J, Lee DM, Pendleton N et al. Association of cognitive performance with the metabolic syndrome and with glycaemia in middle-aged and older European men: the European Male Ageing Study. Diabetes Metab. Res. Rev. 26(8), 668-676 (2010)
67. Bokura H, Nagai A, Oguro H, Kobayashi S, Yamaguchi S. The association of metabolic syndrome with executive dysfunction independent of subclinical ischemic brain lesions in Japanese adults. Dement. Geriatr. Cogn. Disord. 30(6), 479-485 (2010)
68. Yaffe K, Weston AL, Blackwell T, Krueger KA. The metabolic syndrome and development of cognitive impairment among older women. Arch. Neurol. 66(3), 324-328 (2009)
69. Ronnemaa E, Zethelius B, Sundelof J et al. Impaired insulin secretion increases the risk of Alzheimer disease. Neurology 71(14), 1065-1071 (2008)
70. Baker LD, Cross DJ, Minoshima S, Belongia D, Watson GS, Craft S. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early Type 2 diabetes. Arch. Neurol. 68(1), 51-57 (2011)
71. Matsuzaki T, Sasaki K, Tanizaki Y et al. Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology 75(9), 764-770 (2010)
72. Mcneilly AD, Williamson R, Sutherland C, Balfour DJ, Stewart CA. High fat feeding promotes simultaneous decline in insulin sensitivity and cognitive performance in a delayed matching and non-matching to position task. Behav. Brain Res. 217(1), 134-141 (2011)
73. Cornier MA, Dabelea D, Hernandez TL et al. The metabolic syndrome. Endocr. Rev. 29(7), 777-822 (2008)
74. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu. Rev. Med. 46, 223-234 (1995)
75. Nicholl ID, Bucala R. Advanced glycation endproducts and cigarette smoking. Cell Mol. Biol.(Noisy-le-grand) 44(7), 1025-1033 (1998)
76. O'brien J, Morrissey PA. Nutritional and toxicological aspects of the Maillard browning reaction in foods. Crit. Rev. Food Sci. Nutr. 28(3), 211-248 (1989)
77. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 44(2), 129-146 (2001)
78. Monnier VM, Glomb M, Elgawish A, Sell DR. The mechanism of collagen cross-linking in diabetes: a puzzle nearing resolution. Diabetes 45(Suppl. 3), S67-S72 (1996)
79. Monnier VM, Cerami A. Nonenzymatic browning in vivo: possible process for aging of long-lived proteins. Science 211(4481), 491-493 (1981)
80. Chiarelli F, De Martino M, Mezzetti A et al. Advanced glycation end products in children and adolescents with diabetes: relation to glycemic control and early microvascular complications. J Pediatr. 134(4), 486-491 (1999)
81. Jerums G, Panagiotopoulos S, Forbes J, Osicka T, Cooper M. Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease. Arch. Biochem. Biophys. 419(1), 55-62 (2003)
82. Lee AT, Cerami A. Role of glycation in aging. Ann NY Acad. Sci. 663, 63-70 (1992)
83. Srikanth V, Maczurek A, Phan T et al. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiol. Aging 32(5), 763-777 (2011)
84. Shuvaev VV, Laffont I, Serot JM, Fujii J, Taniguchi N, Siest G. Increased protein glycation in cerebrospinal fluid of Alzheimer's disease. Neurobiol. Aging 22(3), 397-402 (2001)
85. Ahmed N, Ahmed U, Thornalley PJ, Hager K, Fleischer G, Munch G. Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment. J Neurochem. 92(2), 255-263 (2005)
86. Riviere S, Birlouez-Aragon I, Vellas B. Plasma protein glycation in Alzheimer's disease. Glycoconj. J 15(10), 1039-1042 (1998)
87. Emanuele E, D'angelo A, Tomaino C et al. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch. Neurol. 62(11), 1734-1736 (2005)
88. Ghidoni R, Benussi L, Glionna M et al. Decreased plasma levels of soluble receptor for advanced glycation end products in mild cognitive impairment. J Neural. Transm. 115(7), 1047-1050 (2008)
89. Xu WL, Qiu CX, Wahlin A, Winblad B, Fratiglioni L. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 63(7), 1181-1186 (2004)
90. Wu JH, Haan MN, Liang J, Ghosh D, Gonzalez HM, Herman WH. Impact of antidiabetic medications on physical and cognitive functioning of older Mexican Americans with diabetes mellitus: a population-based cohort study. Ann Epidemiol. 13(5), 369-376 (2003)
91. Xu WL, Von Strauss E, Qiu CX, Winblad B, Fratiglioni L. Uncontrolled diabetes increases the risk of Alzheimer's disease: a population-based cohort study. Diabetologia 52(6), 1031-1039 (2009)
92. Gao L, Matthews FE, Sargeant LA, Brayne C. An investigation of the population impact of variation in HbA1c levels in older people in England and Wales: from a population based multi-centre longitudinal study. BMC Public Health 8, 54 (2008)
93. Shorr RI, De Rekeneire N, Resnick HE et al. Glycemia and cognitive function in older adults using glucose-lowering drugs. J Nutr. Health Aging 10(4), 297-301 (2006)
94. Yaffe K, Blackwell T, Whitmer RA, Krueger K, Barrett CE. Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women. J Nutr. Health Aging 10(4), 293-295 (2006)
95. Risner ME, Saunders AM, Altman JF et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 6(4), 246-254 (2006)
96. Reger MA, Watson GS, Green PS et al. Intranasal insulin improves cognition and modulates b-amyloid in early AD. Neurology 70(6), 440-448 (2008)
97. Plastino M, Fava A, Pirritano D et al. Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus Type-2. J Neurol. Sci. 288(1-2), 112-116 (2010)
98. Mcclean PL, Parthsarathy V, Faivre E, Holscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci. 31(17), 6587-6594 (2011)
99. Rodriguez-Rivera J, Denner L, Dineley KT. Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status. Behav. Brain Res. 216(1), 255-261 (2011)
100. Gasparini L, Gouras GK, Wang R et al. Stimulation of b-amyloid precursor protein trafficking by insulin reduces intraneuronal b-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci. 21(8), 2561-2570 (2001)
101. Selkoe DJ. The cell biology of b-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol 8(11), 447-453 (1998)
102. Cole SL, Vassar R. The Alzheimer's disease b-secretase enzyme, BACE1. Mol. Neurodegener. 2, 22 (2007)
103. Vetrivel KS, Zhang YW, Xu H, Thinakaran G. Pathological and physiological functions of presenilins. Mol. Neurodegener. 1, 4 (2006)
104. Chen Y, Zhou K, Wang R et al. Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad. Sci. USA 106(10), 3907-3912 (2009)
105. De Felice FG, Vieira MN, Bomfim TR et al. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Ab oligomers. Proc Natl Acad. Sci. USA 106(6), 1971-1976 (2009)
106. Noh RM, Graveling AJ, Frier BM. Medically minimising the impact of hypoglycaemia in Type 2 diabetes: a review. Expert Opin. Pharmacother. 12(14), 2161-2175 (2011)
107. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with Type 2 diabetes mellitus. JAMA 301(15), 1565-1572 (2009)
108. Bruce DG, Davis WA, Casey GP et al. Severe hypoglycaemia and cognitive impairment in older patients with diabetes: the Fremantle Diabetes Study. Diabetologia 52(9), 1808-1815 (2009)
109. Bauduceau B, Doucet J, Bordier L, Garcia C, Dupuy O, Mayaudon H. Hypoglycaemia and dementia in diabetic patients. Diabetes Metab. 36(Suppl. 3), S106-S111 (2010)